Tesamorelin

Tesamorelin – Injectable (2 mg × 10 Vials / 5 mg × 10 Vials / 10 mg × 10 Vials)

Tesamorelin is a stabilized synthetic analog of growth hormone–releasing hormone (GHRH), engineered with a trans-3-hexenoic acid modification that enhances resistance to enzymatic degradation and significantly prolongs half-life. It is widely studied for its ability to increase endogenous growth hormone secretion, promote lipolysis, reduce visceral adipose tissue, and support metabolic function.

Available Formats:

2 mg × 10 sterile vials
5 mg × 10 sterile vials
10 mg × 10 sterile vials

Chemical Composition:

Type: Modified GHRH analog
Sequence: 44–amino acid peptide with N-terminal trans-3-hexenoic acid modification
Molecular Weight: ~5.1 kDa

Administration (Injectable):

Supplied as a lyophilized peptide intended for subcutaneous injection following reconstitution with bacteriostatic water.
Research protocols typically use once-daily injections due to Tesamorelin’s extended half-life and consistent GH-releasing activity.

Benefits & Key Features:

Potent stimulator of endogenous GH secretion
Clinically documented reduction in visceral fat mass
Supports lipolysis and improved metabolic profile
Improves recovery and tissue repair associated with elevated GH/IGF-1
Highly stable lyophilized formula in sealed sterile vials

Product Notes:

For research and laboratory use only.
Must be reconstituted before administration.
Sterile, injectable-grade peptide.